PDR MEMBER LOGIN:
  • PDR Search

    Required field
  • OMEGALIFE-3™ and OMEGALIFE-3™ Resolv DS


    DIETARY SUPPLEMENT

    ----------

    OMEGALIFE-3™ and OMEGALIFE-3™ Resolv
    DS

    Omega-3 Fatty Acid Supplementation

    DESCRIPTION

    OmegaLife-3™ and OmegaLife-3™ Resolv are a blend of omega-3 fatty acids designed to help maintain healthy cardiovascular and cerebral function.

    OmegaLife-3™ is an amber-colored, semi-viscous, fat-soluble liquid softgel. Each serving of OmegaLife-3™ contains the following active ingredients: 800 mg eicosapentaenoic acid (EPA), 400 mg docosahexaenoic acid (DHA), and vitamin E. In addition, it also contains the inactive ingredients gelatin, glycerin, purified water, and orange oil. OmegaLife-3™ has been molecularly distilled to ensure exceptionally pure oil to provide higher levels of EPA and DHA and includes orange oil to prevent a fishy aftertaste.

    OmegaLife-3™ Resolv is a patent pending, semi-opaque, semi-viscous, fat-soluble liquid softgel. Each serving of OmegaLife-3™ Resolv contains the following active ingredients: 1000 mg eicosapentaenoic acid (EPA), 500 mg docosahexaenoic acid (DHA), and 120 mg vitamin E. In addition, it also contains the inactive ingredients; beeswax, Gaultheria procumbens (wintergreen oil), soy lecithin, l-arginine, special antioxidants blend (rosemary extract, sunflower oil, mixed natural tocopherols, L-ascorbyl palmitate), fish gelatin, glycerin, purified water. OmegaLife-3™ Resolv has been molecularly distilled to ensure exceptionally pure oil to provide higher levels of EPA and DHA; in addition this product includes wintergreen oil to prevent a fishy aftertaste.1


    1
    THESE STATEMENTS HAVE NOT BEEN EVALUATED BY THE FOOD AND DRUG ADMINISTRATION. THIS PRODUCT IS NOT INTENDED TO DIAGNOSE, TREAT, CURE, OR PREVENT ANY DISEASE.

    BENEFITS AND RESEARCH

    Clinical research suggests fish oil can help support proper brain and eye health. In 2002 the FDA approved supplementation of DHA in infant formula. DHA is potentially important in fetal and infant neural development, in that DHA and arachidonic acid have been shown to be incorporated into brain and retinal cell membranes—particularly during the third trimester of pregnancy and early infant life.

    DHA is the predominant structural fatty acid in the central nervous system and in the retina of the eyes.

    EPA supports the synthesis of important compounds in the body. EPA is the precursor of thromboxane and leukotriene, compounds involved in supporting healthy circulation. They also promote healthy blood vessels.

    Evidence is accumulating that increasing intakes of EPA and DHA can decrease the risk thrombosis, decrease triglyceride levels, and decrease inflammation.

    The U.S. Food and Drug Administration (FDA) has stated, "Supportive but not conclusive research shows that consumption of EPA and DHA omega-3 fatty acids may reduce the risk of coronary heart disease."1

    SUGGESTED USAGE

    Take four softgels daily with water.

    SAFETY AND WARNINGS

    OmegaLife-3™ and OmegaLife-3 Resolve are well tolerated. As with any dietary supplement, some gastrointestinal discomfort may be experienced.

    HOW SUPPLIED

    Available in softgels.

    REFERENCES

    Barter P, Ginsberg HN. Effectiveness of combined statin plus omega-3 fatty acid therapy for mixed dyslipidemia. Am J Cardiol. 2008;102(8):1040-1045

    Lee JH, Harris WS, et al. Omega-3 fatty acids for cardioprotection. Mayo Clin Proc. 2008;83(3):324-332.

    SanGiovanni JP, Chew EY, Sperduto RD, et al. The relationship of dietary omega-3 long-chain polyunsaturated fatty acid intake with incident age-related macular degeneration: AREDS report no. 23. Arch Ophthalmol. 2008;126(9):1274-1279.

    SanGiovanni JP, Parra-Cabrera S, Colditz GA, Berkey CS, Dwyer JT. Meta-analysis of dietary essential fatty acids and long-chain polyunsaturated fatty acids as they relate to visual resolution acuity in healthy preterm infants. Pediatrics 2000;105:1292-8.

    Kris-Etherton PM, Harris WS, Appel LJ. Omega-3 fatty acids and cardiovascular disease: new recommendations from the American Heart Association. Arterioscler Thromb Vasc Biol. 2003;23(2):151-152.